ROSELLINI, MATTEO
 Distribuzione geografica
Continente #
NA - Nord America 456
AS - Asia 376
EU - Europa 363
AF - Africa 33
SA - Sud America 2
Totale 1.230
Nazione #
US - Stati Uniti d'America 453
SG - Singapore 223
IT - Italia 129
CN - Cina 90
SE - Svezia 63
DE - Germania 33
IN - India 31
CI - Costa d'Avorio 30
IE - Irlanda 28
CH - Svizzera 23
FI - Finlandia 22
JO - Giordania 17
NL - Olanda 16
BG - Bulgaria 13
GB - Regno Unito 13
ID - Indonesia 9
FR - Francia 6
RU - Federazione Russa 6
BE - Belgio 4
CA - Canada 3
TG - Togo 3
AR - Argentina 2
AT - Austria 2
HK - Hong Kong 2
JP - Giappone 2
PK - Pakistan 2
PL - Polonia 2
ES - Italia 1
GR - Grecia 1
LV - Lettonia 1
Totale 1.230
Città #
Singapore 204
Santa Clara 96
Boardman 52
Chandler 40
Bologna 31
Abidjan 30
Dublin 28
Bern 22
Ashburn 21
Amman 17
Helsinki 17
Guangzhou 14
Sofia 13
Hyderabad 12
Turin 11
Fairfield 10
Princeton 10
Shanghai 9
Southend 9
Beijing 7
Jakarta 7
Rome 7
Milan 6
Berlin 5
Enschede 5
Falkenstein 5
Hoofddorp 5
Lappeenranta 5
Redmond 5
San Polo di Torrile 5
Boydton 4
Brussels 4
Bühl 4
Florence 4
Nanjing 4
Rimini 4
Cambridge 3
Columbus 3
Lomé 3
Modena 3
Munich 3
Paris 3
San Diego 3
Telgate 3
Xi'an 3
Amsterdam 2
Ann Arbor 2
Bron 2
Cagliari 2
Chengdu 2
Cipolletti 2
Deiva Marina 2
Frankfurt am Main 2
Gatineau 2
Genoa 2
Gujrat 2
Hong Kong 2
Knivsta 2
Legnano 2
Los Angeles 2
Moscow 2
North Kuta 2
Norwalk 2
Phoenix 2
Seattle 2
Shenzhen 2
Shijiazhuang 2
Slough 2
Tokyo 2
Verona 2
Warsaw 2
Athens 1
Bangalore 1
Bari 1
Cedar Knolls 1
Des Moines 1
Fort Worth 1
Fuzhou 1
Handan 1
Hangzhou 1
Harbin 1
Houston 1
Jiaozuo 1
Jinan 1
Leicester 1
London 1
Lugano 1
New York 1
Oderzo 1
Padova 1
Pamplona 1
Qingdao 1
Redwood City 1
Riga 1
Taizhou 1
Tianjin 1
Toronto 1
Trento 1
Verdellino 1
Vienna 1
Totale 840
Nome #
Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience 70
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis 65
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials 54
Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials 49
Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials 48
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: A systematic review 44
The molecular characteristics of non‐clear cell renal cell carcinoma: What’s the story morning glory? 42
Overall survival with adjuvant pembrolizumab in renal cell carcinoma — the shock of the lightning 39
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy 38
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis 37
Bone targeting agents in patients with metastatic prostate cancer: State of the art 37
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw 36
Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis 36
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis 36
A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience 36
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study 34
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma 33
Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma 32
Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers 30
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt 29
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study 27
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study 26
Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer 26
Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy 25
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study 23
Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials 23
Current androgen receptor antagonists under investigation for resistant prostate cancer 23
Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer 23
TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab 22
Treating prostate cancer by antibody-drug conjugates 21
An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma 19
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials 19
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis 18
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations 18
How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma? 17
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies 17
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma? 15
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis 15
An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma 14
The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study 14
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy 14
Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: A critical overview of recent evidence 13
Prostate cancer and novel pharmacological treatment options - what's new for 2022? 13
Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma 13
What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it? 10
Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial 9
Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives 9
Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study 9
Totale 1.320
Categoria #
all - tutte 6.346
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.346


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202112 0 0 0 0 0 0 0 0 0 7 0 5
2021/202292 0 0 1 3 2 1 8 21 6 3 33 14
2022/2023365 5 15 7 17 36 35 21 19 95 11 55 49
2023/2024228 19 36 21 14 18 27 7 17 13 16 24 16
2024/2025623 72 153 104 87 166 41 0 0 0 0 0 0
Totale 1.320